Impact of Tricuspid Regurgitation on Clinical Outcomes: The COAPT Trial

Heart FailureTherapy and Intervention

Aetiology-based clinical scenarios predict outcomes of transcatheter edge-to-edge tricuspid valve repair of functional tricuspid regurgitation

Eur J Heart Fail.

Schlotter F, Orban M, Rommel KP, Besler C, von Roeder M, Braun D, Unterhuber M, Borger M, Hagl C, Orban M, Nabauer M, Massberg S, Thiele H, Hausleiter J, Lurz P

doi: 10.1002/ejhf.1547.

Heart Failure

Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio With Transcatheter Mitral Valve Repair Outcomes: A Secondary Analysis of the COAPT Trial

JAMA Cardiol

Lindenfeld J, Abraham WT, Grayburn PA, Kar S, Asch FM, Lim DS, Nie H, Singhal P, Sundareswaran KS, Weissman NJ, Mack MJ, Stone GW, Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (COAPT) Investigators.

doi: 10.1001/jamacardio.2020.7200

Heart, Artery and Coronary Diseases

An Appraisal of the Association of Clinical Outcomes With the Severity of Regurgitant Volume Relative to End-Diastolic Volume in Patients With Secondary Mitral Regurgitation

JAMA Cardiol.

Gaasch WH, Aurigemma GP, Meyer TE

doi: 10.1001/jamacardio.2019.5980.

Heart, Artery and Coronary DiseasesHeart Failure

Predictors of Procedural and Clinical Outcomes in Patients With Symptomatic Tricuspid Regurgitation Undergoing Transcatheter Edge-to-Edge Repair

JACC Cardiovasc Interv.

Besler C, Orban M, Rommel KP, Braun D, Patel M, Hagl C, Borger M, Nabauer M, Massberg S, Thiele H, Hausleiter J, Lurz P

doi: 10.1016/j.jcin.2018.05.002.

Heart, Artery and Coronary DiseasesHeart FailureTherapy and Intervention

Transcatheter Mitral Valve Replacement in Patients with Heart Failure and Secondary Mitral Regurgitation: From COAPT Trial

J Am Coll Cardiol.

Asch FM, Grayburn PA, Siegel RJ, Kar S, Lim DS, Zaroff JG, Mishell JM, Whisenant B, Mack MJ, Lindenfeld J, Abraham WT, Stone GW, Weissman NJ, COAPT Investigators.

doi: 10.1016/j.jacc.2019.09.017.

Heart, Artery and Coronary Diseases

Clinical characteristics, diagnosis, and risk stratification of pulmonary hypertension in severe tricuspid regurgitation and implications for transcatheter tricuspid valve repair

Eur Heart J.

Lurz P, Orban M, Besler C, Braun D, Schlotter F, Noack T, Desch S, Karam N, Kresoja KP, Hagl C, Borger M, Nabauer M, Massberg S, Thiele H, Hausleiter J, Rommel KP

doi: 10.1093/eurheartj/ehaa138.

Heart Failure

Impact of left ventricular ejection fraction on clinical outcomes after left main coronary artery revascularization: results from the randomized EXCEL trial

Eur J Heart Fail.

Thuijs DJFM, Milojevic M, Stone GW, Puskas JD, Serruys PW, Sabik JF 3rd, Dressler O, Crowley A, Head SJ, Kappetein AP

doi: 10.1002/ejhf.1681.

Atrial Fibrillation

Patient-Reported Outcomes and Patient-Reported Experience of Patients With Atrial Fibrillation in the IMPACT-AF Clinical Trial

J Am Heart Assoc

Humphries B, Cox JL, Parkash R, Thabane L, Foster GA, MacKillop J, Nemis-White J, Hamilton L, Ciaccia A, Choudhri SH, Xie F, IMPACT‐AF Investigators.

doi: 10.1161/JAHA.120.019783

Heart, Artery and Coronary DiseasesTherapy and Intervention

3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial